menu ☰
menu ˟

Allergan to acquire Vitae Pharmaceuticals, strengthen dermatology pipeline

14 Sep 2016
Allergan plc announced today it has entered into a definitive agreement to acquire Vitae Pharmaceuticals for $21 per share in cash, for a total value of approximately $639 million.The acquisition will include VTP-43742, a phase 2 first in class, oral...

Click here to view the full article which appeared in Dermatology

Please note

The news articles accessible on the Health Well website have been compiled from various sources that are not controlled by the Institute of Public Health in Ireland (IPH). IPH is therefore not responsible for the content of external websites and the inclusion of a link to an external website from the Health Well should not be understood to be an endorsement of that website.